Pyrazolyl derivatives as bifunctional chelators for labeling tumor-seeking peptides with the fac-[M(CO)3]+ moiety (M = 99mTc, Re): Synthesis, characterization, and biological behavior

Bioconjugate Chemistry

Volumn 16, Issue 2, 2005, Pages 438-449

  Alves, Susana ^a   Paulo, António ^a   Correia, João D G ^a   Gano, Lurdes ^a   Smith, Charles J ^b,c   Hoffman, Timothy J ^b,c   Santos, Isabel ^a  

^a INSTITUTO TECNOLÓGICO E NUCLEAR   (Portugal)

^b University of Missouri   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CHELATION; LIGANDS; RADIOACTIVITY; RHENIUM COMPOUNDS; SYNTHESIS (CHEMICAL); TUMORS;

BI-FUNCTIONAL; BIOLOGICAL BEHAVIOR; BIOLOGICALLY ACTIVE MOLECULES; BUILDING BLOCKES; IN-VITRO; IN-VIVO; LABELINGS; MODEL COMPLEXES; PYRAZOLYL; RADIOLABELLING;

PEPTIDES;

AMINE; BOMBESIN DERIVATIVE; CHELATING AGENT; CYSTEINE; DIPEPTIDE; HISTIDINE; NITROGEN; PYRAZOLE DERIVATIVE; RHENIUM; TECHNETIUM 99M; THYROXINE I 125; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; CHEMICAL REACTION; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIPOPHILICITY; MOUSE; NONHUMAN; PLASMA CLEARANCE; RADIOACTIVITY; RADIOCHEMISTRY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; URINARY EXCRETION;

EID: 15244347266     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc0497968     Document Type: Article

References (36)

1. Hom, R. K., and Katzenellenbogen, J. A. (1997) Technetium-99m.-Labeled Receptor-Specific Small-Molecule Radiopharmaceuticals: Recent Development and Encouraging Results Nucl. Med. Biol. 24, 485-498.
2. Dilworth, J. R., and Parrott, S. J. (1998) The Biomedical Chemistry of Technetium and Rhenium. Chem. Soc. Rev. 27, 43.
3. Jurisson, S. S., and Lydon, J. D. (1999) Potential technetium small molecules radiopharmaceuticals. Chem. Rev. 99, 2205-2218.
4. 99mTc-labeled small petides as diagnostic radiopharmaceuticals. Chem. Rev. 99, 2235-2268.
5. Heppeler, A., Froidevaux, S., Eberle, A. N., and Maecke, H. R. (2000) Receptor Targetting for Tumor Localisation and Therapy with Radiopeptides. Curr. Med. Chem. 7, 971-994.
6. Behr, T. M., Gotthardt, M., Barth, A., and Béhé, M. (2001) Imaging tumors with peptide-based radioligands. Q. J. Nucl. Med. 45, 189-200.
7. Okarvi, S. M. (2004) Peptide-Based Radiopharmaceuticals: Future Tools for Diagnostic Imaging of Cancers and Other Diseases. Med. Res. Rev. 24, 357-397.
8. Kwekkeboom, D., Krenning, E. P., and de Jong, M. (2000) Peptide Receptor Imaging and Therapy. J. Nucl. Med. 41, 1704-1713.
9. 3]. J. Organomet. Chem. 493, 119-127.
10. - in aqueous solution and its reaction with a bifunctional ligand. J. Am. Chem. Soc. 120, 7987-7988.
11. Metzler-Nolte, N. (2001) Labeling of Biomolecules for Medicinal Applications - Bioorganometallic Chemistry at Its Best. Angew. Chem., Int. Ed. 40, 1040-1043.
12. 99mTc(I) Tricarbonyl Complexes: A Hint for the Future Functionalization of Biomolecules. Bioconjugate Chem. 11, 345-351.
13. Garcia, R., Paulo, A., Domingos, A., Santos, I, Ortner, K., and Alberto, R., (2000) Re and Tc Complexes Containing B-H...M Agostic Interactions as Building Blocks for the Design of Radiopharmaceuticals. J. Am. Chem. Soc. 122, 11240-11241.
14. 99mTc with an In Situ CO Source: Application to a Serotonergic Receptor Ligand. Angew. Chem., Int. Ed. 40, 3062-3066.
15. Correia, J. D. G., Domingos, A., Santos, I, Alberto, R., and Ortner, K. (2001)Re Tricarbonyl Complexes with Ligands Containing P, N, N and P, N, O Donor Atom Set: Synthesis and Structural Characterization. Inorg. Chem. 40, 5147-5151.
16. Garcia, R., Paulo, A., Domingos, A., and Santos, I. (2001) Rhenium(I) Organometallic Complexes with Novel Bis(mercaptoimidazolyl)borates and with Hydrotris(mercaptoimidazolyl)borate: Chemical and Structural Studies. J. Organomet. Chem. 632, 41.
17. 99mTc(I)-Metallocarboranes in Water under Weakly Basic Reaction Conditions. Inorg. Chem. 43, 3032-3034.
18. Bernard, J., Ortner, K., Spingler, B., Pietzsch, H.-J., and Alberto, R. (2003) Aqueous Synthesis of Derivatized Cyclopentadienyl Complexes of Technetium and Rhenium Directed toward Radiopharmaceutical Application. Inorg. Chem. 42, 1014-1022.
19. +. Chem.-Eur. J. 9, 2053-2061.
20. + Moiety. J. Chem. Soc., Dalton Trans. 24, 4714-4719.
21. Vitor, R., Alves, S., Correia, J. D. G., Paulo, A., and Santos, I. (2004)Rhenium(I)- and Technetium(I) Tricarbonyl Complexes Anchored by Bifunctional Pyrazole-Diamine and Pyrazole-Dithioether Chelators. J. Organomet. Chem. 689, 4764-4774.
22. + Core. Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine 6 (Nicolini, M., Mazzi, U., Eds.) pp 139-142, SGEditoriali, Padova.
23. 13,14] Bombesin Analogues Inhibit Growth of Small Cell Lung Cancer In Vitro and In Vivo. Life Sci. 37, 105-113.
24. Qin, Y., Ertl, T., Cai, R.-Z., Halmos, G., and Schally, A. V. (1994) Inhibitory Effect of Bombesin Receptor Antagonist RC-3095 on the Growth of Human Pancreatic Cancer Cells In Vivo and In Vitro. Cancer Res. 54, 1035-1041.
25. Qin, Y., Ertl, T., Cai, R.-Z., Horvath, J. E., Groot, K., and Schally, A. V. (1995) Antagonists of Bombesin/Gastrin-releasing Peptide Inhibit Growth of SW-1990 Human Pancreatic Adenocarcinoma and Production of Cyclic AMP. Int. J. Cancer 63, 257-262.
26. Plonowski, A., Nagy, A., Schally, A. V., Sun, B., Groot, K., and Halmos, G. (2000) In Vivo Inhibition of PC-3 Human Androgen-independent Prostate Cancer by a Targeted Cytotoxic Bombesin Analogue, AN-215. Int. J. Cancer 88, 652-657.
27. Breeman, W. A. P., Hofland, L. J., De Jong, M., Bernard, B. F., Srinivasan, A., Kwekkeboom, D. J., Visser, T. J., and Krenning, E. P. (1999) Evaluation of Radiolabeled Bombesin Analogues for Receptor-targeted Scintigraphy and Radiotherapy. Int. J. Cancer 81, 658-665.
28. 4]Bombesin, a New Radioligand for Bombesin-receptor Scintigraphy. Int. J. Cancer 83, 657-663.
29. Sorrel, T. N., and Malachowski, M. R. (1983) Mononuclear Three-Coordinate Copper (I) Complexes: Synthesis, Structure and Reaction with Carbon Monoxide. Inorg. Chem. 22, 1883-1887.
30. Haanstra, W. G., Driessen, W. L., Van Roon, M., Stoffels, A. L. E., and Reedijk, J. (1989) Unusual Chelating Properties of the Ligand 1,8-Bis (3, 5-dimethyl-1-pyrazolyl)-3,6-dithiaoctane (bddo). Crystal Structures of Ni(bddo)(NCS)2, Zn(bddo)(NCS)2 and Cd2(bddo9(NCS)4. J. Chem. Soc., Dalton Trans. 2309-2314.
31. Van Berkel, P. M., Driessen, W. L., Parlevliet, F. J., Reedijk, J., and Sherrington, D. C. (1997) Metal-uptake Behaviour by a Novel Pyrazole-Containing Ligand Immobilised on to Poly(Glycidylmethacrylate-co-trimethylolpropane- trimethacrylate). Eur. Polym. J. 33, 129-135.
32. Lopez, P., Seipelt, G., Merkling, P., Sturz, L., Alvarez, J., Dolle, A., Zeidler, M. D., Cerdan, S., and Ballesteros, P. (1999) N-2-(Azol-1(2)yl) ethyliminodiacetic acids: A novel Series of Gd(III) Chelators as T2 Relaxation Agents for Magnetic Resonance Imaging. Bioorg. Med. Chem. 7, 517-527.
33. 2: An In vitro/in vivo assessment of the Targeting Ability of this New Radiopharmaceutical for PC-3 Human Prostate Cancer Cells. Nucl. Med. Biol. 30, 101-109.
34. Smith, C. J., Volkert, W. A., and Hoffman, T. J. (2002) Gastrin Releasing Peptide (GRP) Receptor Targeted Radiopharmaceuticals: A Concise Update. Nucl. Med. Biol. 30, 861-868.
35. 2]: Syntheses, Radiolabeling, and In Vitro/In Vivo Studies Where Dpr = Diaminopropionic Acid. Anticancer Res. 23, 63-70.
36. 3. Cancer Res. 63, 4082-4088.